Diabetic Gastroparesis Treatment Market Report 2026

Diabetic Gastroparesis Treatment Market Overview

• Diabetic Gastroparesis Treatment market size has reached to $4.05 billion in 2025 • Expected to grow to $5.47 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Diabetes Prevalence Ignites Momentum In Diabetic Gastroparesis Treatment Market • Market Trend: Avenacy Launches Metoclopramide Injection To Enhance Diabetic Gastroparesis Treatment • North America was the largest region and fastest growing region.

What Is Covered Under Diabetic Gastroparesis Treatment Market?

Diabetic gastroparesis treatment involves managing delayed stomach emptying in diabetic patients, typically through medications like prokinetics, antiemetics, dietary changes, or, in severe cases, surgical interventions. These treatments aim to alleviate symptoms such as nausea, vomiting, and abdominal discomfort. The main diabetic gastroparesis treatments are medication and surgery. Medications such as gastroprokinetic agents, antiemetic agents, and botulinum toxin are used to diagnose, treat, cure, prevent, or alleviate the symptoms of a medical condition or disease. These are administered as orals and injectables for the treatment of compensated gastroparesis and gastric failure. They are distributed by hospital pharmacies, retail pharmacies, and other channels for hospitals, homecare, specialty clinics, and others.

What Is The Diabetic Gastroparesis Treatment Market Growth Forecast?

The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $5.47 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to development of novel prokinetic agents, increased disease awareness, expansion of specialty clinics, demand for long-term symptom control, innovation in gastric stimulation technologies. Major trends in the forecast period include increasing use of prokinetic drug therapies, rising focus on symptom-based disease management, expansion of combination pharmacological treatments, growing adoption of minimally invasive interventions, increased emphasis on dietary and lifestyle management.

Global Diabetic Gastroparesis Treatment Market Segmentation

1) By Treatment: Medication, Surgery 2) By Route Of Administration: Oral, Injectables 3) By Indication: Compensated Gastroparesis, Gastric Failure 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants 2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage

What Are The Drivers Of The Diabetic Gastroparesis Treatment Market?

The increasing prevalence of diabetes is expected to propel the growth of the diabetic gastroparesis treatment market going forward. The prevalence of diabetes refers to the proportion or percentage of the population that has been diagnosed with diabetes at a specific point in time. The use of diabetic gastroparesis treatment is primarily aimed at managing the symptoms and complications associated with this condition, which is a common complication of diabetes. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international not-for-profit federation of national diabetes associations, an estimated 589 million adults aged 20–79 were living with diabetes worldwide, with that number projected to reach 853 million by 2050. Therefore, the increasing prevalence of diabetes is driving the growth of the diabetic gastroparesis treatment industry. The rising number of surgical procedures is expected to propel the growth of the diabetic gastroparesis treatment market going forward. Surgery refers to a medical specialty and branch of medicine that involves the treatment of diseases, injuries, or conditions through operative procedures. Surgical procedures in diabetic patients that have caused post-surgical gastroparesis include Nissen fundoplication, gastrectomy, gastric bypass surgery, pancreatectomy, vagotomy, and cholecystectomy by injuring the vague nerve that coordinates food movement through the digestive tract. For instance, in June 2024, American Society of Plastic Surgeons, a US-based non-profit organization management, minimally invasive procedures experienced a 7 percent growth in 2023, exceeding the growth rate of surgical procedures by 2 percent. Therefore, the rising number of surgical procedures drives the diabetic gastroparesis treatment industry.

Key Players In The Global Diabetic Gastroparesis Treatment Market

Major companies operating in the diabetic gastroparesis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC

Global Diabetic Gastroparesis Treatment Market Trends and Insights

Major companies operating in the diabetic gastroparesis treatment market are innovating advanced solutions, such as small bowel intubation, to enhance diagnostic accuracy and treatment effectiveness. Small bowel intubation involves inserting a tube into the small intestine, enabling more precise monitoring and therapeutic interventions for conditions like diabetic gastroparesis, where gastric motility is impaired. For instance, in September 2024, Avenacy, a US-based pharmaceutical company launched Metoclopramide Injection (USP) in Unites States. Metoclopramide Injection (USP) is an injectable medication designed for multiple indications, notably including the relief of symptoms associated with diabetic gastroparesis. It helps prevent nausea and vomiting related to chemotherapy and surgery. The injection assists in small bowel intubation in cases where conventional methods fail to pass a tube through the pylorus. It is used to stimulate gastric emptying and facilitate barium transit during radiological procedures.

Regional Outlook

North America was the largest region in the diabetic gastroparesis treatment market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetic Gastroparesis Treatment Market?

The diabetic gastroparesis treatment market consists of revenues earned by entities by providing services such as medical evaluation, medication management, dietary consultation, insulin adjustment, lifestyle modifications, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic gastroparesis treatment market also includes sales of metoclopramide, erythromycin, domperidone, promethazine, and ondansetron (Zofran). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetic Gastroparesis Treatment Market Report 2026?

The diabetic gastroparesis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic gastroparesis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.